Video Experimental Relacionado
Updated: Jul 7, 2026
04:48
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Antitrombina III y enfermedad arterial
T W Meade1, J Cooper, G J Miller
1MRC Epidemiology and Medical Care Unit, Northwick Park Hospital, Harrow, UK.
Lancet (London, England)
|October 5, 1991
Resumen
Tanto los niveles bajos como altos de antitrombina III aumentan el riesgo de enfermedad arterial. Este estudio prospectivo encontró una mayor mortalidad por enfermedad arterial en hombres con niveles extremos de antitrombina III en comparación con aquellos con niveles moderados.
Área de la Ciencia:
- Ciencias Cardiovasculares Ciencias Cardiovasculares
- Hematología Hematología.
Sus antecedentes:
- Los estudios transversales indican un vínculo entre los niveles de antitrombina III y el riesgo de enfermedad arterial.
- Tanto los niveles bajos como los altos de antitrombina III se han asociado con un mayor riesgo, particularmente para la enfermedad isquémica del corazón (EII).
Objetivo del estudio:
- Investigar prospectivamente la relación entre los niveles de antitrombina III y la muerte posterior por enfermedad arterial.
Principales métodos:
- El Estudio del Corazón de Northwick Park analizó prospectivamente a 893 hombres.
- Se evaluaron los niveles de antitrombina III y se correlacionaron con la actividad del factor VII y los niveles plasmáticos de fibrinógeno.
Principales resultados:
- Se observó una correlación directa entre los niveles de antitrombina III y una mayor actividad del factor VII y el fibrinógeno plasmático.
- La mortalidad por enfermedad arterial fue mayor en los tercios más bajos y más altos de la distribución de antitrombina III en comparación con el tercio medio.
Conclusiones:
- Tanto los niveles extremadamente bajos como los extremadamente altos de antitrombina III están asociados con un mayor riesgo de muerte por enfermedad arterial.
- Estos hallazgos destacan una posible relación en forma de U entre los niveles de antitrombina III y la mortalidad por enfermedad arterial.
Videos de Conceptos Relacionados
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:18Endocarditis III: Medical Management
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...